Last updated on July 2018

Safety and Efficacy Study for Treatment of Anemia in ESRD Newly Initiated Dialysis Patients


Brief description of study

The purpose of this study is to determine whether FG-4592 (roxadustat) is safe and effective in the treatment of anemia in patients who have just begun dialysis treatment for end stage renal disease.

Detailed Study Description

There is a screening period of up to 6 weeks, a treatment period of a minimum of 52 weeks and a maximum of approximately up to 3 years after last patient is randomized, and a post-treatment follow-up period of 4 weeks. A total of up to 900 patients will be randomized in a 1:1 ratio to receive either open-label FG-4592 or Active Control (Epoetin alfa).

Clinical Study Identifier: NCT02052310

Contact Investigators or Research Sites near you

Start Over

Trial Coordinator

Investigational Site
Sumter, SC United States

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.